Phase 1 Dose Escalation Trial of Ilorasertib, a Dual Aurora/VEGF Receptor Kinase Inhibitor, in Patients With Hematologic Malignancies

BACKGROUND: Ilorasertib (ABT-348) is a novel inhibitor of Aurora kinase, vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptors, and the Src families of tyrosine kinases. Ilorasertib alone or in combination with azacitidine demonstrated activity in preclinical models...

Full description

Saved in:
Bibliographic Details
Published in:Invest New Drugs
Main Authors: Garcia-Manero, Guillermo, Tibes, Raoul, Kadia, Tapan, Kantarjian, Hagop, Arellano, Martha, Knight, Emily A., Xiong, Hao, Qin, Qin, Munasinghe, Wijith, Roberts-Rapp, Lisa, Ansell, Peter, Albert, Daniel H., Oliver, Brian, McKee, Mark D., Ricker, Justin L., Khoury, Hanna Jean
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5563391/
https://ncbi.nlm.nih.gov/pubmed/25933833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0242-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items